Home/Pipeline/Severe Asthma (FFA4 receptor)

Severe Asthma (FFA4 receptor)

Severe Asthma

Pre-clinicalActive

Key Facts

Indication

Severe Asthma

Phase

Pre-clinical

Status

Active

Company

Keltic Pharma Therapeutics

About Keltic Pharma Therapeutics

Keltic Pharma Therapeutics is a private, preclinical-stage biotech company developing a proprietary drug discovery platform called PEPSMOL©. This platform aims to create 'synthetic biologics' to target hard-to-drug GPCRs, with initial in-house programs targeting severe asthma, malaria, Alzheimer's disease, and schizophrenia. The company, founded by three renowned University of Glasgow professors, is pre-revenue and has secured non-dilutive grant funding, including a SMART Grant from Innovate UK in 2024, to advance its platform and pipeline.

View full company profile

Therapeutic Areas

Inflammatory Diseases Infectious Diseases Neurology Psychiatry

Other Severe Asthma Drugs

Drug	Company	Phase	Status
Depemokimab (GSK3511294)	GSK	Phase III	Active
Spiro Neuromodulation System	Spiro Medical	Phase 2	Active
KN-002	Kinaset Therapeutics	Pre-clinical	Active
FB704A	Oneness Biotech	Phase 1	Active
GB-0895	Generate Biomedicines	Phase 3	Active
Verekitug (UPB-101)	Upstream Bio	Phase 2	Completed